(redirected from biomarker)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
References in periodicals archive ?
This was appropriate in the early stages of biomarker validation.
Insight into the terms included in a biomarker agreement, together with real world clause examples
A following section discusses the technologies (diagnostics and assays) to detect biomarkers and authors have emphasized the preclinical and clinical manifestation of the injury/disease process.
Analyzing actual contract agreements allows assessment of the following: What are the precise biomarker rights granted or optioned?
New Developments Total Market Size and Forecast Nervous System Disorder Biomarker Market by Geographical Region Competitor Summary CHAPTER NINE: MARKET SUMMARY Market Considerations Market Overview Medical Biomarkers Market by Application Medical Biomarkers Market by Geographical Region CHAPTER TEN: COMPANY PROFILES Introduction 20/20 GeneSystems, Inc.
Biomarkers have wide spread applications and are used in several sectors including pharmaceuticals due to their high sensitivity and efficacy.
Biomarkers to Aid Reduction of Drug Development Time and Costs, Spurring Growth in the European Biomarker Analysis Market
Chapter 3 provides a review of the leading biomarker deals since 2007.
By 2015, we estimate the global CNS biomarker market will account for around 15% of global biomarker sales to be worth over US$3.
Aushon Biosystems, a provider of multiplex immunoassay products and services, and Pacific Biomarkers, a leading provider of clinical biomarker laboratory services, have announced today that Pacific Biomarkers has adopted the Cira platform for multiplex biomarker analysis.
By 2015, the biomarker market is forecast to be worth over US$20 billion as the cardiovascular and CNS biomarker market segments begin to mature with the launch of a number of diagnostic tests to guide the treatment of neuropsychiatric and neurodegenerative diseases.
The novel test that BG Medicine expects to develop aims to use the biomarker discovered by CARIM to identify plaque rupture in patients early, for instance, when the blockage is temporary or not complete and has not yet caused the common signs and symptoms of heart attack or stroke.